News

A study of 576 patient inquiries found that remote care for MG may need to support urgent questions and clinician involvement.

Different monoclonal antibody treatments improve different aspects of myasthenia gravis, including daily function and muscle strength.

A new review finds rare disease studies often record only age and sex, missing key demographic factors that shape patients’ care.

The FDA has approved expanding the label of efgartigimod alfa-fcab to include adult patients with any serotype of generalized MG.

A study found that a ketogenic diet may reduce symptom severity and fatigue in people with MG, though larger trials are needed.

Researchers discovered differences in when and how breathing disruptions during sleep occurred in individuals with AChR-MG and MuSK-MG.

Many patients with myasthenia gravis rely on steroids long term and often stop or restart treatment, showing care is not consistent.

Claseprubart led to rapid and clinically meaningful symptom improvement in generalized MG, with benefits seen as early as one week.

A retrospective, multicenter analysis of 46 adults with AChR-positive generalized MG supports the safety and efficacy of efgartigimod.

Measuring AChR antibodies over time can help predict if myasthenia gravis symptoms will worsen in stable patients, according to a new study.